The clinicopathological features of patients with membranous nephropathy

Background Membranous nephropathy (MN) represents a distinct glomerular disease which has been considered as a major cause of nephrotic syndrome (NS) in adults. Evidences show that the clinicopathological features of MN are various among MN cases. This study aimed to summarize and analyze the clinicopathological features of patients with MN. Methods A total of 231 MN patients were recruited in this study. Their clinical and pathological features were collected and analyzed according to their age, gender, pathological stages, and anti-phospholipase A2 receptor (anti-PLA2R) antibodies tests. Results Among the 231 MN cases, the ratio of male to female was 1.47 and the mean age was 47.43±14.32 years. Altogether, 163 (70.6%) cases were positive for NS. Their serum antiPLA2R, body mass index, total cholesterol, triglyceride, low density lipoprotein cholesterol, D2, IgA, and IgE were increased, but IgG was decreased. The majority of the patients were middle aged and old aged. In addition, the pathological stage was significantly correlated with gender (P=0.038), creatinine, (P=0.021) and IgE (P=0.003). A total of 74.9% MN patients were found to be positive for anti-PLA2R antibodies, and they were more likely to have abnormal serum indices. Conclusion The major clinicopathological characteristics of MN patients are summarized in this study. Male and elder MN cases are likely to have rapid disease progression. Advanced pathological stages and being positive for anti-PLA2R antibodies may be potential indicators for disease activity of MN.

[1]  B. Liu,et al.  Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy , 2017, Scientific Reports.

[2]  Bo Chen,et al.  Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy , 2017, Scientific Reports.

[3]  Lin Sun,et al.  [Diagnostic value of renal phospholipase A2 receptor and serum anti-phospholipase A2 receptor antibody in membranous nephropathy]. , 2017, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[4]  C. Hao,et al.  Renal Phospholipase A2 Receptor and the Clinical Features of Idiopathic Membranous Nephropathy , 2017, Chinese medical journal.

[5]  F. Cosio,et al.  Recurrent Membranous Nephropathy After Kidney Transplantation: Treatment and Long-Term Implications , 2016, Transplantation.

[6]  H. Debiec,et al.  Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. , 2015, Molecular immunology.

[7]  J. Klein,et al.  Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy , 2015, Proteomics.

[8]  H. Debiec,et al.  Pathophysiological advances in membranous nephropathy: time for a shift in patient's care , 2015, The Lancet.

[9]  Y. Wang,et al.  Clinicopathological analysis of idiopathic membranous nephropathy in young adults. , 2015, Genetics and molecular research : GMR.

[10]  C. Greenfeld,et al.  Overview of Current and Alternative Therapies for Idiopathic Membranous Nephropathy , 2015, Pharmacotherapy.

[11]  Huhai Zhang,et al.  Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis , 2015, Scientific Reports.

[12]  J. Klein,et al.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. , 2015, The New England journal of medicine.

[13]  U. Panzer,et al.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[14]  M. Ando,et al.  Patient Age and the Prognosis of Idiopathic Membranous Nephropathy , 2014, PloS one.

[15]  Javier Zamora,et al.  Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. , 2014, The Cochrane database of systematic reviews.

[16]  U. Panzer,et al.  PLA2R Antibody Levels and Clinical Outcome in Patients with Membranous Nephropathy and Non-Nephrotic Range Proteinuria under Treatment with Inhibitors of the Renin-Angiotensin System , 2014, PloS one.

[17]  H. Debiec,et al.  Immunopathogenesis of membranous nephropathy: an update , 2014, Seminars in Immunopathology.

[18]  C. Ponticelli,et al.  Glomerular diseases: membranous nephropathy--a modern view. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[19]  T. Muthukumar,et al.  Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy , 2014, Journal of Nephrology.

[20]  J. Wetzels,et al.  Treatment of idiopathic membranous nephropathy , 2013, Nature Reviews Nephrology.

[21]  L. Beck,et al.  Membranous nephropathy: not just a disease for adults , 2013, Pediatric Nephrology.

[22]  M. Praga,et al.  Glomerular disease: Predicting outcomes in idiopathic membranous nephropathy , 2012, Nature Reviews Nephrology.

[23]  D. Yang,et al.  Elevated Levels of Immunoglobulin E May Indicate Steroid Resistance or Relapse in Adult Primary Nephrotic Syndrome, Especially in Minimal Change Nephrotic Syndrome , 2011, The Journal of international medical research.

[24]  J. Lewis,et al.  Membranous nephropathy with crescents. , 2011, Journal of the American Society of Nephrology : JASN.

[25]  G. Remuzzi,et al.  Membranous nephropathy associated with IgG4-related disease. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  A. Cybulsky Membranous nephropathy. , 2011, Contributions to nephrology.

[27]  克治 桑門 海外論文紹介 : M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy , 2010 .

[28]  C. Ponticelli,et al.  Management of idiopathic membranous nephropathy , 2010, Expert opinion on pharmacotherapy.

[29]  C. Ponticelli,et al.  Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy? , 2010, Journal of nephrology.

[30]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[31]  刘双信,et al.  Membranous nephropathy , 2008 .

[32]  Zhi-Hong Liu,et al.  Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. , 2004, Kidney international.

[33]  N. Yorioka,et al.  Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. , 2004, Kidney international.

[34]  F. Salvatore,et al.  Gender and the progression of chronic renal diseases: does apoptosis make the difference? , 2004, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[35]  Kuender D Yang,et al.  Implication of serum IgE in childhood nephrotic syndrome , 2003, Pediatric Nephrology.

[36]  T. Miyawaki,et al.  Clinicopathological characteristics of the focal and segmental form of idiopathic membranous nephropathy: Comparison with the typical form of this disease , 1997, Acta paediatrica Japonica : Overseas edition.